Skip to main content
. 2015 Apr 12;6(17):15681–15689. doi: 10.18632/oncotarget.3804

Table 1. Methods used to test for KRAS, NRAS and BRAF mutations.

KRAS NRAS BRAF
Method* codon
12/13
N (%)
codon
59
N(%)
codon
61
N (%)
codon
117
N (%)
codon
146
N(%)
codon
12/13
N (%)
codon
59
N (%)
codon
61
N(%)
codon
117
N (%)
codon
146
N (%)
codon
600
N (%)
Next generation sequencing
Illumina MiSeq Oncopanet (Illumina)[25] 10
(5,8)
10
(5,8)
10
(5,8)
10
(5,8)
10
(5,8)
10
(5,8)
10
(5,8)
10
(5,8)
0
(0,0)
0
(0,0)
10
(5,8)
IonTorrent (Life Sciences) 20
(11,7)
20
(11,7)
20
(11,7)
20
(11,7)
20
(11,7)
20
(11,7)
20
(11,7)
20
(11,7)
10
(5,8)
20
(11,7)
20
(11,7)
Sequencing
Sanger Sequencing 51
(29,8)
61
(35,7)
61
(35,7)
73
(42,7)
84
(19,2)
74
(43,3)
84
(49,2)
74
(434)
83
(48,6)
73
(487)
51
(29,8)
HRM + Sanger Sequencing 60
(35.1)
60
(15.1)
60
(35.1)
30
(17.5)
30
(17.5)
.30
117.5)
30
(17.5)
30
(17.5)
0
(0.0)
0
(0.0)
40
(23.4)
Real-time PCR + Sanger sequencing 10
(5,8)
0
(0,0)
0
(0,0)
0
(0,0)
0
(0,0)
10
(5,8)
0
(0,0)
10
(5,8)
0
(0,0)
0
(0,0)
10
(5,8)
Pyrosequencing 0
(0,0)
0
(0,0)
0
(0,0)
0
(0,0)
0
(0,0)
0
(0,0)
0
(0,0)
0
(0,0)
10
(5,8)
10
(5,8)
0
(0,0)
Other assays
Therascreen KRAS/NRAS/BRAF Pyrokit (Qiagen) 10
(5,8)
0
(0,0)
10
(5,8)
0
(0,0)
0
(0,0)
10
(5,8)
0
(0,0)
10
(5,8)
0
(0,0)
0
(0,0)
10
(5,8)
Therascreen RAS extension Pyrokit (Qiagen) 0
(0,0)
10
(5,8)
0
(0,0)
10
(5,8)
10
(5,8)
0
(0,0)
10
(5,8)
0
(0,0)
10
(5,8)
10
(5,8)
-
Sequenom MassArray (Sequenom) 10
(5,8)
0
(0,0)
10
(5,8)
10
(5,8)
10
(5,8)
10
(5,8)
10
(5,8)
10
(5,8)
10
(5,8)
10
(5,8)
10
(5,8)
Total samples tested 171
(100)
161
(94,2)
171
(100)
153
(89,5)
161
(95,9)
164
(95,9)
164
(95,9)
161
(95,9)
123
(71,9)
123
(71,9)
151
(88,3)*
*

Total 171 samples received from 17 labs, 10 samples per lab, 1 lab sent 11 DNA samples;

*

4 laboratories only test BRAF on request by the physician.

Note: for each codon. the most frequently used method is highlighted in bold